Clarivate (NYSE:CLVT) Announces Earnings Results, Beats Expectations By $0.04 EPS

Clarivate (NYSE:CLVT) released its earnings results on Tuesday. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.16 by $0.04, FiscalAI reports. Clarivate had a negative net margin of 15.83% and a positive return on equity of 8.55%. The firm had revenue of $617.00 million during the quarter, compared to analysts’ expectations of $604.79 million. Clarivate updated its FY 2026 guidance to 0.700-0.800 EPS.

Clarivate Stock Performance

Clarivate stock opened at $1.68 on Tuesday. The stock’s 50-day moving average is $2.82 and its 200-day moving average is $3.48. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -2.94 and a beta of 1.51. The company has a debt-to-equity ratio of 0.90, a current ratio of 0.87 and a quick ratio of 0.87. Clarivate has a 12 month low of $1.66 and a 12 month high of $4.91.

Insider Activity

In related news, insider Bar Veinstein sold 309,902 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $3.74, for a total transaction of $1,159,033.48. Following the completion of the sale, the insider owned 848,811 shares of the company’s stock, valued at approximately $3,174,553.14. This represents a 26.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 23.18% of the company’s stock.

Institutional Trading of Clarivate

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC lifted its stake in shares of Clarivate by 204.3% during the fourth quarter. Virtu Financial LLC now owns 49,960 shares of the company’s stock worth $167,000 after purchasing an additional 33,544 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Clarivate by 38.4% during the 4th quarter. Invesco Ltd. now owns 1,327,520 shares of the company’s stock valued at $4,434,000 after buying an additional 368,531 shares during the period. Vident Advisory LLC raised its holdings in shares of Clarivate by 3.3% during the 4th quarter. Vident Advisory LLC now owns 185,821 shares of the company’s stock valued at $621,000 after buying an additional 5,980 shares during the period. SkyView Investment Advisors LLC lifted its position in Clarivate by 1.4% during the 4th quarter. SkyView Investment Advisors LLC now owns 413,728 shares of the company’s stock worth $1,382,000 after acquiring an additional 5,830 shares in the last quarter. Finally, Empowered Funds LLC boosted its holdings in Clarivate by 587.2% in the 4th quarter. Empowered Funds LLC now owns 388,670 shares of the company’s stock worth $1,298,000 after acquiring an additional 332,110 shares during the period. 85.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CLVT. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research note on Monday, December 29th. Morgan Stanley reaffirmed an “underweight” rating and set a $3.00 price objective (down previously from $5.00) on shares of Clarivate in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group lowered shares of Clarivate from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $4.20 to $3.60 in a report on Thursday, January 8th. Three investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $3.70.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.